Stage I TNBC cancer patients were analyzed by tumor size: T1a (< 0.5 cm), T1b (> 0.5 cm and < 1.0 cm) and T1c (>1.0 cm and < 2.0 cm). A Cox proportional hazard model was used to determine significance of variables.Results:Of the 610 stage I TNBC patients, 183 had tumor sizes...
Cancer metastasis is a multistep process that is characterized by the following cascade of events: local invasion, intravasation, extravasation, micrometastatic colony formation, and cell proliferation [10]. In essence, progression of cancer can be categorized into three primary stages: (1) primary ...
President’s Cancer Panel Report of the Chairman. 2000;2001. Lee CN, Chang Y, Adimorah N, Belkora JK, Moy B, Partridge AH, et al. Decision making about surgery for early-stage breast cancer. J Am Coll Surg 2012;214:1–10. Article PubMed Google Scholar Zikmund-Fisher BJ, Couper ...
Results of pivotal phase III trials investigating palbociclib in patients with advanced-stage oestrogen receptor (ER)-positive breast cancer have demonstrated a substantial improvement in progression-free survival, with a well-tolerated toxicity profile. Mechanisms of acquired resistance to CDK4/6 ...
San Antonio Breast Cancer Symposium 2013: San Antonio, TX. Poortmans P, et al. Irradiation of the internal mammary and medial supraclavicular lymph nodes in stage I to III breast cancer: 10-year results of the EORTC Radiation Oncology and Breast Cancer Groups phase III trial. European Cancer ...
Clinical observation on moxibustion for limb functional rehabilitation in early stage of post-surgery breast cancer patients. Zhongguo Zhongyiyao Keji, 2012, 19(5): 453-454. [29]Xu HF, Zhao BX. A brief summary of mechanism of moxibustion. Shanghai Zhenjiu Zazhi, 2012, 31(1): 6-9. [30...
Nanoparticles have many potential benefits for diagnosing and treating metastatic cancer, including the ability to transport complex molecular cargoes to the major sites of metastasis, such as the lungs, liver and lymph nodes, as well as targeting to specific cell populations within these organs. ...
(LVA) in treating breast cancer-related lymphedema. We evaluate patient outcome at 1 and 3 months post surgery, duration of the surgery, and quality of the anastomosis. At 3 months, patient outcome improves. Furthermore, a steep decline in duration of time required to complete the anastomosis...
(6). This is problematic in the clinical management of diseases such as prostate cancer in which changes in androgen action signifies endstage disease--biological or chemical markers of differential androgen action would be useful in targeting therapies. There is little information on cellular factors...
Kleppe et al (NPJ Breast Cancer, 2015, 1:15005). Juergens et al (Cancer Discovery, 1:2011, 599-607). Primary Examiner: GODDARD, LAURA B Attorney, Agent or Firm: BROWN RUDNICK LLP (BOSTON, MASSACHUSETTS, US) Parent Case Data: